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macular hole ILMs we found an average thickness of 1.3  8 
0.65   m, and in diabetic macular edema ILMs an average 
thickness of 6.2  8 1.4   m.  Conclusions: In heavy BBG-as-
sisted ILM peeling we observed no intraoperative or postop-
erative complications after a mean follow-up of 12 months. 
Heavy BBG could be an effective and safe vehicle for staining 
the ILM.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 The internal limiting membrane (ILM) is a transpar-
ent, thin structure comprised of the basement membrane 
of the Müller cells. The Müller cells are essential for the 
maintenance of the retina’s normal structure and func-
tion. Removal of the ILM improves the surgical outcome 
of several vitreoretinal conditions, including epiretinal 
membranes, macular edemas, and macular holes  [1, 2] . 
However, difficulties in visualization of the normally 
completely translucent ILM can increase surgical time 
and the risk of intraoperative trauma to retinal struc-
tures.
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 Abstract 
 Background: Brilliant blue G (BBG) is frequently used in 
chromovitrectomy to facilitate internal limiting membrane 
(ILM) peeling. A study was initiated to evaluate if heavy BBG 
is safe and effective in staining the ILM.  Methods: We stud-
ied 30 eyes, 23 with idiopathic macular holes and 7 of pa-
tients with diabetic macular edema. Removal of the ILMs 
was assisted by heavy BBG staining. In cases with histopath-
ological correlation the ILMs were evaluated with hematox-
ylin and eosin, Masson’s trichrome, periodic acid-Schiff and 
glial fibrillary acidic protein staining. In addition, immuno-
histochemistry was also performed using specific antibod-
ies for vimentin, neuron-specific enolase, factor VIII and 
CD68. Using the Image-Pro Plus software of Media Cyber-
netics Co. we found an average thickness in ILMs.  Results: 
Of the ILM specimens sent, 19/30 (63.33%) could not be pro-
cessed properly because of the limited sample material, rec-
ognizing only fragments of dispersed fibrillar material. In 
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 Staining of the ILM is widely accepted by ophthalmic 
surgeons for safer and more convenient removal of the 
ILM  [3, 4] . Indocyanine green and trypan blue staining 
have greatly facilitated ILM visualization and peeling 
during vitreoretinal surgery. However, numerous reports 
have shown the potential toxicity of these dyes in experi-
mental models and in clinical use  [5–12] , stressing the 
need for a safe and effective alternative.
 The purpose of this study is to report the clinical ex-
perience and the histopathological changes of the ILM of 
eyes submitted to vitrectomy and ILM peeling using 
heavy brilliant blue G (BBG) as staining agent.
 Materials and Methods 
 Heavy BBG (Brilliant Peel  ) was obtained from Fluoron 
GmbH, Ulm, Germany (via Geuder AG, Heidelberg, Germany). 
In addition to regular BBG, 13% heavy water (D 2 O) is included, 
resulting in a density of 1.018 g/cm 3 .
 All patients had follow-up including best corrected visual acu-
ity, complete slitlamp examination, measurement of central mac-
ular thickness using optical coherence tomography (OCT; Top-
con 3D OCT 2000), and fluorescein angiography (Topcon TRC 
50DX). The OCT was repeated at months 2, 4, 8, and 12, including 
measuring the macular thickness. The mean follow-up was 12 
months.
 Posterior vitrectomy was performed on 30 eyes of 30 patients 
presenting with macular holes and diabetic macular edema. Stan-
dard phacoemulsification was performed when needed. Surgery 
consisted of three-port pars plana vitrectomy with induction of a 
posterior vitreous detachment by suction using the vitrectomy 
cutter. BBG, 0.1 ml at a concentration of 0.25 mg/ml, was then 
gently injected in the vitreous cavity without fluid-air exchange 
and with the infusion line clamped. Immediately after the injec-
tion, the infusion line was opened and the dye was removed via 
active aspiration with a soft-tip needle ( fig.  1 a, b). The area of 
staining was classified according to the size of the stained area: 
restricted to the 500-  m macular area (grade 1); outside the mac-
ula but not exceeding the vascular arcades (grade 2), and staining 
beyond the vascular arcades (grade 3).
 Removal of the ILM was performed using 23-gauge ILM dis-
posable forceps ( fig.  1 c, d) and the tissue was collected in 10% 
formaldehyde. ILMs were evaluated using various stains includ-
ing hematoxylin and eosin, Masson’s trichrome, periodic acid-
Schiff and glial fibrillary acidic protein. In addition, immunohis-
tochemistry was also performed using specific antibodies for vi-
mentin, neuron-specific enolase, factor VIII and CD68. In 19 out 
of 30 cases the ILM could not be processed properly because of 
the small sample size.
 Of the 11 cases that could be processed 5 (45.45%) were from 
idiopathic macular holes and 6 (54.55%) from diabetic macular 
edema.
 The thickness of the ILM in the evaluated specimens was also 
measured with the Image-Pro Plus software of Media Cybernetics 
Co. 
a b
c d
 Fig. 1. Application and removal of heavy 
BBG as well as peeling of the ILM stained 
with heavy BBG. 
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 Results 
 Between December 2009 and December 2010, 30 eyes 
of 30 patients were studied. This study complies with the 
Declaration of Helsinki and the Good Clinical Practice 
guidelines. All subjects studied gave written informed 
consent. Of these, 23 had macular holes [12 eyes (52%) 
stage III, 9 eyes (39%) stage IV, and 2 eyes (9%) with a my-
opic macular hole]. Sixteen patients (70%) were female and 
7 patients (30%) were male. The remaining 7 patients (4 
males and 3 females) had diffuse diabetic macular edema 
with a mean central macular thickness of 413   m on OCT.
 The primary closure rate of macular hole after one 
surgery, as assessed by OCT, was 87% (20 out of 23 eyes). 
Patients with persistent macular hole underwent a second 
pars plana vitrectomy and fluid-gas exchange with a 
100% macular hole closure rate.
 We studied all 30 ILM specimens obtained after pars 
plana vitrectomy and BBG staining. In 25 eyes the color-
ing was graded as 3 (83%) and in 5 eyes as grade 2 (17%). 
The vast majority of membranes studied (28/30, 93%) 
were visibly ‘wrapped’ by the blue dye. They were includ-
ed to perform hematoxylin and eosin staining, Masson’s 
trichrome, periodic acid-Schiff and glial fibrillary acidic 
protein staining, as well as immunohistochemistry using 
antibodies specific for vimentin, neuron-specific enolase, 
factor VIII, and CD68 ( fig. 2 ). Nineteen out of the 30 ILM 
specimens sent (63.33%) could not be processed properly 
because of the limited sample material, recognizing on-
ly fragments of dispersed fibrillar material. Eighteen 
(94.73%) were from macular holes and the remaining 
(5.26%) from diabetic macular edema. A study measuring 
membrane thickness using the Image-Pro Plus software 
(Media Cybernetics Co.) found in macular hole ILMs an 
average thickness of 1.3  8 0.65   m, and in diabetic mac-
ular edema ILMs an average thickness of 6.2  8 1.4   m. 
ILMs of all eyes showed satisfactory staining despite the 
immediate irrigation of the dye following instillation. 
 Discussion 
 BBG, also known as acid blue 90 or Coomassie Bril-
liant Blue G-250, is a blue dye (color index 42655) with a 
molecular weight of 854.02 g/mol and the molecular for-
mula of C 47 H 48 N 3 NaO 7 S 2 (sodium salt). It has long been 
used for protein staining in the field of biology as it binds 
nonspecifically to virtually all proteins. In a model of bo-
vine retina, application of BBG at a concentration of 0.25 
mg/ml with an exposure time less than 60 s did not cause 
irreversible effects on the electroretinogram and seems to 
be safe for intraocular administration  [13] . In rat eyes in-
travitreal doses of BBG up to 10 mg/ml did not cause 
morphological changes as revealed by light microscopy, 
but electron microscopy analysis showed cyst formation 
in the inner retinal cells at concentrations above 1 mg/ml. 
No apoptosis was detected and no reduction on the elec-
troretinogram waves was noted after 14 or 60 days  [14] . 
In primate eyes the ILM was clearly stained after intra-
vitreal injection of 0.5 mg/ml BBG  [15] . Clinical data are 
consistent with experimental data and suggest that the 
use of BBG at a concentration of 0.25 mg/ml is safe for 
clinical use.
 Several studies suggested that the ILM plays a signifi-
cant role in the development and treatment of several 
macular pathologies such as macular hole and diabetic 
macular edema  [16, 17] . The ILM also plays an important 
part in macular edema secondary to central retinal and 
branch vein occlusion  [18] . Surgical removal of the ILM 
has proven to be effective both anatomically and func-
tionally  [16] . It is rather challenging to peel and complete-
ly remove the unstained ILM completely because of its 
transparency. Proper visualization via staining not only 
makes the procedure more successful but also less trau-
matic.
 The use of dyes such as indocyanine green and trypan 
blue has become widespread to assist in the removal of 
the ILM and epiretinal membranes. Adverse effects of in-
a b
 Fig. 2. Immunohistochemistry of the ILM 
with an antibody against CD68 to detect 
cells of the macrophage lineage;  b repre-
sents a digital inversion of  a . 
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docyanine green on the retina have been reported in sev-
eral papers  [5–10] while trypan blue results in a rather 
faint staining  [11, 12, 19] .
 Since Enaida et al.  [21] described the use of BBG, sev-
eral reports have reported on its usefulness for staining 
the ILM  [13–15, 20, 22–24] . These studies showed that 
this dye is not toxic, neither in vivo nor in vitro. No dose-
dependent or time-dependent toxicity has been associ-
ated with its use. A low concentration is sufficient and 
obviates the need for fluid-air exchange.
 Heavy BBG was created by adding heavy water (deu-
terium oxide, D 2 O), which is water containing the hydro-
gen isotope deuterium, to a BBG solution in a final con-
centration of 13%. The osmolarity of the solution is 306 
mosm  [24] . With this formula of BBG the surgical stain-
ing time is shorter compared with standard BBG, reduc-
ing both the surgical time and the retinal light exposure. 
 Gerding et al.  [25] reported in an experimental model 
of hydrodynamics of fluids that heavy BBG had a larger 
area of staining than traditional BBG.
 A second advantage of heavy BBG is its higher-than-
water density. The affinity of BBG to proteins may cause 
staining of other intraocular structures, allowing it to vi-
sualize continuous curvilinear capsulorhexis. Inadver-
tent staining during vitreoretinal surgery of the lens cap-
sule could interfere with visualization issues. Conversely, 
heavy BBG sinks to the bottom of the vitreous cavity after 
intravitreal injection and thus avoids direct contact of the 
dye to the posterior lens capsule, while still allowing for 
ILM staining.
 In our 30 eyes undergoing ILM peeling after heavy 
BBG staining we observed no intraoperative or postop-
erative complications after a mean follow-up of 12 
months. We therefore conclude that the new heavy BBG 
could be an effective and safe vehicle for staining the 
ILM.
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